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ABSTRACT
Background: Social support has been shown to be an important factor in improving depression symptom
outcomes, yet less is known regarding its impact on antidepressant medication adherence. This study sought
to evaluate the role of perceived social support on adherence to new antidepressant medication prescriptions
in later-life depression.
Methods: Data from two prospective observational studies of participants ≥60 years old, diagnosed with
depression, and recently prescribed a new antidepressant (N = 452). Perceived social support was measured
using a subscale of the Duke Social Support Index and medication adherence was assessed using a validated
self-report measure.
Results: At four-month follow up, 68% of patients reported that they were adherent to antidepressant
medication. Examining the overall sample, logistic regression analysis demonstrated no significant
relationship between perceived social support and medication adherence. However, when stratifying the
sample by social support, race, and gender, adherence significantly differed by race and gender in those with
inadequate social support: Among those with low social support, African-American females were significantly
less likely to adhere to depression treatment than white females (OR = 4.82, 95% CI = 1.14–20.28,
p = 0.032) and white males (OR = 3.50, 95% CI = 1.03–11.92, p = 0.045).
Conclusions: There is a significant difference in antidepressant medication adherence by race and gender
in those with inadequate social support. Tailored treatment interventions for low social support should be
sensitive to racial and gender differences.
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Introduction
Despite improved recognition and diagnosis of
later-life depression, adherence to antidepressant
medication remains low (Datto et al., 2002).
Studies suggest that upwards of 40% to 75% of
older adults do not take prescribed antidepressants
or terminate treatment prematurely (Kales et al.,
2013; Burnett-Zeigler et al., 2014; Kales et al.,
2016). Non-adherence to treatment has been
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linked to worsening depression outcomes, in-
creased health care utilization, decreased functional
status, and increased morbidity in older adults
(Kales et al., 2013).
A potentially crucial time for medication
adherence is in the early treatment phase. Receipt
of an antidepressant, often in the primary care
setting, is often a patient’s first encounter with and
point of entry into the mental healthcare system.
Stopping a medication early in treatment may
prevent patients from further engaging in care. The
acute treatment phase thus serves a critical role in
establishing patient adherence and is also a high-
risk period for patient suicide (Valenstein et al.,
2009). Given the high rates of non-adherence to
antidepressant medications, a better understanding
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of the potentially modifiable factors that influence
treatment adherence in the early treatment period
is needed.
In our previous work, we examined the impact of
potentially modifiable and non-modifiable factors
on antidepressant medication adherence in later-
life depression (Kales et al., 2013; Burnett-Zeigler
et al., 2014; Kales et al., 2016). We found that
there were significant racial and gender differences
in antidepressant adherence in older adults, with
non-adherence higher among African-American
females. In the present study, we sought to further
examine the associations between the race–gender
differences in adherence we previously found and
the modifiable factor of social support.
Social support is the physical and emotional
reassurance provided to people by those they
associate within their daily lives (Schaefer et al.,
1981). Its protective effects are well documented
in the literature regarding its role in maintaining
health and decreasing vulnerability to physical and
mental illnesses in older adults (Hays et al., 2001;
Holt-Lunstad et al., 2010). The positive influence
of social support on depression outcomes has
been documented in the literature as well as its
ability to buffer the adverse psychological effects
created by stress (Kurlowicz, 1993). Social support
is now known to be a critical part of recovery
from depression with positive outcomes, including
improvement in depressive symptomatology and
lessening time to remission (George et al., 1989;
Bosworth et al., 2002).
Studies have demonstrated that there are
gender differences in the importance of social
support, with women typically having larger
support networks and maintaining more supportive
relationships than men (Krause, 2006). Women
without such supports have been found across
several studies to be more sensitive to the depresso-
genic effects of low social support (Olstad et al.,
2001; Kendler et al., 2005). In women exposed
to stressful life events, social support appears to
reduce the risk of development of subsequent de-
pressive symptoms to a greater degree as compared
to men (Elliott, 2001; Dalgard et al., 2006).
While the evidence demonstrates that social
support is an important factor in preventing both
the onset and progression of depression in later-
life (Blazer, 2005), less is known regarding the
role of social support on antidepressant medication
adherence (Voils et al., 2005; Lee et al., 2010).
Subjective social support has been found in
one study (Voils et al., 2005) to be associated
with greater antidepressant adherence in older
patients with depression. Higher levels of perceived
social support have previously been shown to be
significantly associated with increased adherence
with non-psychiatric medications for conditions,
such as diabetes, heart disease, hypertension, and
HIV (Voils et al., 2005; Wu et al., 2013). Given
the importance of social support on multiple facets
of the depression trajectory in older adults, we
predicted that social support would be associated
with the ability of older participants to adhere to
antidepressant treatment. Factors such as feeling
supported during depression recovery, sense of
family and friend involvement in treatment, and
access to additional support services may underlie
these results.
The goal of this study was to evaluate the
role of perceived social support on adherence to
new antidepressant medication prescriptions in the
acute treatment phase of later-life depression. It was
hypothesized that higher perceived social support
would be positively associated with antidepressant
adherence. Given our previous finding of racial and
gender differences in adherence to antidepressant
medications and studies demonstrating gender
differences in social support mitigating depressive
symptoms, in sub-analyses we were interested in
further evaluating potential race–gender differences
in perceived social support and antidepressant
adherence. It was hypothesized that women
without these supports would be less adherent to
antidepressant medication treatment.
Methods
Study design
Data for this study were obtained by combining
samples from two concurrent prospective obser-
vational studies focused on examining the effect
of various factors on antidepressant medication
adherence within the acute treatment phase (first
four months). Patients were assessed over two time
points, at baseline and at four-month follow up.
This study was approved by and in accordance with
the University of Michigan Medical School, the VA
Ann Arbor Healthcare System, and Wayne State
University institutional review boards.
Setting
In the first study (National Institute of Mental
Health, 5R21MH073002), participants were re-
cruited from 13 primary care clinics affiliated with
the University of Michigan Health Care System
(N = 183). These clinics were located in Ann
Arbor, Michigan and surrounding communities.
In the second study (Veterans Affairs Health
Services Research & Development, IIR 04-104-
2), participants were recruited from three Veterans
Affairs Medical Centers located in Michigan
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(N = 269), from both primary care and mental
health clinics. Each study had identical inclusion
and exclusion criteria, similar protocol including
baseline and four-month follow up measures, and
occurred concurrently. Study participants were
recruited between 2007 and 2011. This study
design has been previously described (Kales et al.,
2013; 2016).
Selection of participants
Study participants were age 60 years or older,
diagnosed with depression (Patient Health Ques-
tionnaire 9 [PHQ-9] score ≥5), and given a new
antidepressant prescription by their primary care
provider or psychiatrist. A lower PHQ-9 cut-
off score was used given the observation that
older adults as well as certain subgroups (e.g.
African-Americans and men) may be prone to
deny depression (Gallo and Rabins, 1999). In
order to have an inclusive sample of depressed
older adults, a lower PHQ-9 score indicative of
mild depression together with a physician decision
to prescribe an antidepressant was considered
clinically significant depression. Participants were
excluded if they suffered from another serious
mental illness, including psychosis or bipolar
disorder, cognitive impairment (≥3 errors on
Six-Item Screener) (Callahan et al., 2002), had
a legal guardian, or were actively suicidal. All
the remaining participants were eligible for study
participation.
Data collection and processing
Study assessments were conducted at study entry
and at a four-month follow up. The four-month
follow up was chosen because the early phase of
treatment is a particularly critical time period with
an increased risk of treatment discontinuation as
well as vulnerability to suicide (Valenstein et al.,
2009). Assessments were conducted by research
assistants and all participants provided written
informed consent prior to study participation.
Measures
A structured telephone interview at baseline
included assessment of both modifiable and non-
modifiable factors shown to potentially influence
depression treatment adherence. Demographic
variables were collected, including age, race,
gender, marital status, and education. Illness
burden of depression was assessed with the PHQ-9
and past antidepressant use. Anxiety was assessed
by the Hospital Anxiety and Depression Scale
(HADS-A) and Anxiety Severity Index (ASI-
R). Functional status assessment was based on
instrumental and basic (Katz ADL) activities of
daily living, perceived global functioning measured
by the 12-Item Short-Form Health Survey (SF-
12) physical component scale (PCS), mental
health component scale (MCS), and executive
function was measured by the Wechsler letter-
number sequencing. Participants were given the
telephone interview as soon as possible after the
antidepressant recommendation; the mean time to
initial interview from treatment recommendation
date was 47 ± 15 days.
The Duke Social Support Index (DSSI) is
a 35-item battery developed for the NIMH
Epidemiologic Catchment Area (ECA) Program
that measures social support (George et al., 1989;
Landerman et al., 1989; Hughes et al., 1993).
This index is designed to assess the social network
of older adults and the support provided by that
network. Five dimensions of social support are
included: satisfaction with social support, perceived
social support, frequency of social interaction, size
of the social network, and instrumental support.
In the present study, only a 10-item subscale of
the DSSI focusing on perceived social support
was measured (ex. feeling useful, listened to,
satisfied with relationships, etc.). As in prior
research, “inadequate” or “low” social support was
defined as a score of ≤23 (determined on the
basis of population norms from the ECA study,
representing 13.5% of the ECA sample) (George
et al., 1989; Hughes et al., 1993). Scores greater
than 23 indicated adequate levels of perceived
social support.
At the four-month follow up, adherence was
measured using the validated self-report adherence
question from the Brief Medication Questionnaire
that asks the participants how consistently they took
medication in the week prior (Svarstad et al., 1999).
An adherence of less than 80% was considered to
be inadequate, with those missing two or more daily
doses in a given week considered non-adherent
(Krivoy et al., 2015). For veterans within our study
who received prescriptions through the VA (N =
255), these data were used to calculate Medication
Possession Ratios (MPRs) for patients to provide an
objective measure of antidepressant coverage over
the study period. TheMPR is the number of days of
medication supplied divided by the number of days
in the time interval. An MPR threshold of less than
80% was considered inadequate coverage (Fortney
et al., 2011).
Data analysis
Descriptive analyses included means and standard
deviations for continuous variables and frequencies
for categorical variables. Unadjusted compar-
isons of continuous and categorical baseline
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demographic and clinical variables between those
with inadequate versus adequate social support
were performed using t-tests and χ2-tests, respect-
ively. Logistic regression analysis was also used to
compare four-month adherence across perceived
social support by race-by-gender subgroups, after
adjusting for baseline characteristics previously
shown or thought to potentially influence depres-
sion treatment adherence (Zivin and Kales, 2008).
Covariates included demographics (age, education,
marital status), illness burden (determined by any
prior use of an antidepressant, PCS, MCS, PHQ-
9, HADS-A, ASI), cognitive function (IADLs,
Weschler), treatment site (psychiatry vs. primary
care), and veteran status. Baseline covariates were
organized as sets of variables and entered hierarch-
ically in a predefined order with the potentially
confounding contextual variables entered first in
order to sequentially to assess their influence on
adherence and to control for their effects on the
relationship between adherence and social support
by race-by-gender. Demographic characteristics
were entered first, followed by treatment and illness
burden variables, then cognitive function variables,
treatment site, and finally veteran status, and the
final model kept all variables in the model. To assess
for concern that the time lag between treatment
recommendation and initial interview might have
affected the results, we examined the relationship
between initial PHQ-9 score and length of time
between treatment recommendation and initial
interview. All statistical analyses were done using
SAS 9.3 (SAS Institute Inc., Cary NC).
Results
Sample characteristics
A total of 458 participants met eligibility criteria
for the study. One participant was excluded given
that site of care (psychiatry vs. primary care) was
unclear and five participants were excluded due to
missing items on the DSSI. Of the remaining 452
participants, the study cohort was predominantly
male (76%), white (75%), married/partnered
(55%), with a mean age of 66. Sixty-seven percent
of participants in this sample were veterans. The
mean PHQ-9 score among the study sample was
12 (SD ± 6.0).
Of eligible participants, 67% (N= 305) reported
they were adherent to antidepressant medications
at four-month follow up by the BMQ self-
report. Using the MPR among the veteran sample,
adherence was found to be much lower at 53%
(N = 134/255). There was no association between
initial PHQ-9 score and time between treatment
recommendation and initial interview. Initial
PHQ-9 score did not differ between non-adherent
and adherent participants in adjusted analyses.
The mean DSSI score was 23 (score of ≤23
considered inadequate; SD = 4.2), with 46% of the
participants reporting inadequate social support.
Significant baseline characteristics of participants
reporting low social support include age<75,
single, African-American, lower self-rated physical
and mental health (PCS/MCS), and higher self-
ratings of depression (PHQ) and anxiety (HADS-A
and ASI; Table 1).
Main results
Logistic regression analysis of the overall study
sample demonstrated no significant relationship
between perceived social support and four-month
adherence. However, after stratifying the sample
by race and gender, a significant relationship
between race, gender, social support, and treatment
adherence emerged (Table 2). African-American
participants (N = 111) had significantly lower
four-month antidepressant adherence than white
participants (N = 341; χ2 =7.42, df = 1, p =
0.006). Among those with inadequate social
support, analyses across the race by gender
subgroups showed that African-American females
had the lowest adherence rates (40%), followed
by African-American males (51%), white males
(74%), and white females (78%; χ2 = 15.44, df =
3, p = 0.002).
As shown in Table 2, African-American men
and women with low social support have lower
adherence to antidepressant medications as com-
pared to African-American men and women with
adequate social support, although this trend was
not significant. Interestingly, this pattern was
reversed for white participants, with those with
low social support having higher adherence and
those with adequate support demonstrating lower
antidepressant medication adherence.
In logistic regression models (Table 3) using
African-American females with inadequate social
support as the reference group and controlling for
baseline covariates in a sequential fashion, African-
American females with low social support consist-
ently showed significantly lower odds of adherence
as compared to white females with inadequate
support and white males with inadequate support.
Even after controlling for all covariates, African-
American females with low social support showed
4.8 times (95% CI = 1.14-20.28, p = 0.032)
lower odds of antidepressant medication adherence
as compared to white females with inadequate
support. African-American females with adequate
social support showed no significant differences
from other groups. African-American males did not
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Table 1. Characteristics of sample, percent of group, and mean scores
total (N = 452)
adequate social
support (N = 246)
inadequate
social support g
(N = 206)
characteristics N % N % N % p-value
............................................................................................................................................................................................................................................................................................................................
African-American 111 25 48 20 63 31 0.006
Female 108 24 65 26 43 21 0.168
Age≥75 years 63 14 45 18 18 9 0.003
Some college 274 61 151 61 123 60 0.717
Married/with partner 249 55 147 60 102 50 0.029
Past exposure to antidepressant 291 64 158 64 133 65 0.563
Patients seen in MHC 138 31 65 26 73 35 0.038
Veteran 303 67 151 61 152 74 0.005
Physical component summary
of SF12 (PCS)a
37.2 ± 11.3 38.4 ± 11.6 35.7 ± 10.9 0.015
Mental component summary of
SF12 (MCS)a
38.0 ± 11.1 40.9 ± 11.0 34.4 ± 10.1 <0.001
Patient Health Questionnaire
(PHQ-9)b
12.1 ± 6.0 10.1 ± 5.6 14.6 ± 5.5 <0.001
Hospital anxiety depression
scale, anxiety subscale
(HADS-A)c
9.1 ± 4.0 8.0 ± 3.5 10.4 ± 4.2 <0.001
Anxiety sensitivity index (ASI)d 51.6 ± 25.2 46.5 ± 25.0 57.8 ± 24.0 <0.001
Instrumental activities of daily
living scale (IADL Total)e
7.4 ± 1.5 7.4 ± 1.3 7.2 ± 1.7 0.146
Weschler LNSf 8.2 ± 3.7 8.5 ± 3.6 8.0 ± 3.8 0.165
aPossible component summary scores on the 12-item Short-Form Health Survey (SF-12) range from 0 to 100, with higher scores
indicating a greater health.
bPossible scores on the 9-item Patient Health Questionnaire (PHQ-9) range from 0 to 27, with higher scores indicating greater depression.
cPossible scores on the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS) range from 0 to 21, with higher scores
indicating more severe anxiety symptoms.
dPossible scores on subscales 1 and 4 of the Anxiety Sensitivity Index-Revised (ASI-R) range from 0 to 105, with higher scores indicating
greater anxiety.
ePossible scores on the Instrumental Activities of Daily Living (IADL) Scale range from 0 to 8, with higher scores indicating better
functioning.
fPossible scores on the Wechsler letter-number sequencing (LNS) subscale range from 0 to 21, with higher scores indicating better
executive functioning.
g“Inadequate social support” was defined as a score of a DSSI score of ≤23.
Table 2. Adherence by social support by gender by race subgroups, percent
total
(N = 452)
african -
american
females
(N = 43)
white
females
(N = 65)
african -
american
males
(N = 68)
white
males
(N = 276)
N a %b N a %b N a %b N a %b N a %b
.........................................................................................................................................................................................................................................................................................................................
Adequate social support 168 68 12 52 29 69 14 56 113 72
Inadequate social support 137 67 8 40 18 78 22 51 89 74
Total 305 67 20 47 47 72 36 53 202 73
aNumber of patients adherent to antidepressant medication at four-month follow up.
bPercent of patients adherent to antidepressant medication at four-month follow up.
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Table 3. Antidepressant adherence comparison across social support by race by gender subgroups
adjusted for
demographic
characteristics
adjusted for
demographic
characteristics and
illness burden
adjusted for
demographic
characteristics ,
illness burden, and
cognitive function
adjusted for
demographic
characteristics ,
illness burden ,
cognitive function ,
and treatment site
adjusted for
demographic
characteristics ,
illness burden ,
cognitive function ,
treatment site , and
veteran status
group
comparison
odds
ratio
95%
ci
p-
value
odds
ratio
95%
ci
p-
value
odds
ratio
95%
ci
p-
value
odds
ratio
95%
ci
p-
value
odds
ratio
95%
ci
p-
value
...............................................................................................................................................................................................................................................................................................................................................................................................................................................
African-American
female low social
support
(reference)
1.0 – – 1.0 – – 1.0 – – 1.0 – – 1.0 – –
African-American
female adequate
social support
1.48 (0.43–
5.06)
0.536 1.57 (0.45–
5.53)
0.482 1.54 (0.43–
5.53)
0.506 1.51 (0.42–
5.42)
0.524 1.52 (0.42–
5.43)
0.522
African-American
male low Social
support
1.28 (0.43–
3.85)
0.657 1.24 (0.41–
3.78)
0.708 1.28 (0.41–
3.94)
0.669 1.16 (0.37–
3.60)
0.802 1.19 (0.34–
4.17)
0.782
African-American
male adequate
social support
1.52 (0.45–
5.14)
0.499 1.60 (0.46–
5.52)
0.461 1.75 (0.50–
6.14)
0.383 1.60 (0.45–
5.66)
0.467 1.65 (0.43–
6.35)
0.469
White male low
social support
3.58 (1.31–
9.77)
0.013∗ 3.53 (1.27–
9.82)
0.016∗ 3.98 (1.40–
11.30)
0.010∗ 3.37 (1.16–
9.83)
0.026∗ 3.50 (1.03–
11.92)
0.045∗
White male
adequate social
support
3.05 (1.12–
8.28)
0.029∗ 3.29 (1.16–
9.35)
0.025∗ 3.59 (1.24–
10.37)
0.018∗ 3.13 (1.07–
9.21)
0.038∗ 3.24 (0.97–
10.82)
0.057
White female low
social support
4.49 (1.15–
17.55)
0.031∗ 4.12 (1.03–
16.51)
0.045∗ 4.93 (1.18–
20.64)
0.029∗ 4.77 (1.14–
19.94)
0.032∗ 4.82 (1.14–
20.28)
0.032∗
White female
adequate social
support
2.95 (0.96–
9.10)
0.060 2.69 (0.83–
8.70)
0.099 3.05 (0.91–
10.19)
0.070 2.91 (0.87–
9.71)
0.083 2.93 (0.87–
9.84)
0.083
∗p < 0.05.
“Low social support” was defined as a DSSI score of ≤23.
Logistic regression models controlled for demographics (age, education, marital status), illness burden (determined by prior use of an antidepressant, PCS, MCS, PHQ-9, HADS-A, ASI),
cognitive function (IADLs, Weschler), treatment site (psychiatry vs. primary care), and Veteran status. Each set of covariates were added sequentially into the model.
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differ significantly from any of the groups regardless
of level of social support.
Discussion
The present study demonstrates that roughly a
third of older adults from our sample reported non-
adherence to antidepressant medications within the
early phase of treatment. It appears that there is
a significant relationship between race, perceived
social support, and antidepressant adherence.
African-Americans with inadequate social support
had lower levels of antidepressant adherence in the
early treatment phase as compared to white older
adults. There also appeared to be an interaction
of race and gender as well. African-American
females who reported inadequate social support
had the lowest adherence to medications among all
groups and may represent a particularly vulnerable
population in regards to antidepressant treatment
adherence. Of interest, the trend was reversed with
white females, in that those with low levels of
social support actually had improved medication
adherence (78% adherent with low support vs. 69%
adherent with adequate support, NS).
Previous studies have demonstrated varying
perspectives on antidepressant and mental health
treatment efficacy with African-American patients
reporting higher perceived levels of stigma toward
mental health diagnoses and treatment, resulting in
less engagement in care (Prins et al., 2008). Studies
have demonstrated that African-Americans may be
more likely to view antidepressant medications as
non-efficacious or potentially addictive and less
likely to adhere to treatment (Burnett-Zeigler et al.,
2014).
Studies have suggested that there are also gender
differences in the importance of social support
variables, with women typically having larger
social support networks and maintaining more
supportive relationships (Krause, 2006). Women
without these supports have been shown to be
at greater risk of developing depressive symptoms
(Olstad et al., 2001; Kendler et al., 2005). A sense
of community and social network, both family
and spiritual, is very important to the African-
American community. For African-American wo-
men, there may be greater acceptance of utilizing
support from relatives, friends, partners/spouses,
and religious organizations as opposed to more
formal mental health treatment services. African-
American women without these supports may be at
considerably higher risk than whites for subsequent
non-adherence. The idea of the “strong black
woman” may lead African-American women to
believe that they do not have the time to seek
treatment for depression, that depression is a
normal part of aging, or that they should “go it on
their own.” Low levels of social support in African-
American women may also serve as a proxy for
other disparities in access to mental healthcare,
including lack of health insurance, availability of
transportation, and cost of treatment, which may
further impact medication adherence.
It remains unclear why white women with low
social support had a trend of greater medication
adherence rates within this study. One hypothesis
may be that these individuals with low support
find their interaction with the physician to
be more socially rewarding, have an increased
perceived benefit from medication treatment, and
are therefore more likely to comply with treatment
recommendations in an effort to be a “good
patient.” Further, it has been shown that caregiver
and family beliefs about depression treatment can
impact adherence both positively and negatively.
More family support and involvement is not always
helpful at times, especially if family is encouraging
patients not to take medications or adhere to
treatment.
There are several limitations to the current study.
The sample was drawn from outpatient clinics
associated with VA medical centers and university
primary care clinics in southeastern Michigan.
It is possible that the results of our study may
have differed if conducted in another geographic
area. Additionally, our measure of adherence was
provided by self-report for the university study and
it is possible that pharmacy records or pill counts
may have yielded alternative results. However,
as shown in our veteran sample, use of MPRs
predicted even greater rates of non-adherence than
self-report (54% by MPR vs. 33% by BMQ),
suggesting our results may be underestimated
within the university sample.
Our current study only assessed a measure of
perceived social support. It may be that other
aspects of social support (instrumental support,
size of social network, or frequency of social
contacts) may have a greater overall influence on
medication adherence and could be areas of future
inquiry. While we attempted to account for many
factors, such as demographics, illness burden,
cognitive function, veteran status, and site of care,
it is possible that unobserved confounding variables
might mitigate the difference in antidepressant
medication adherence, social support, and race
found in our study. One such factor may be
perceived benefit from treatment. Given the small
sample size within race by gender subgroups, it is
possible that our study is not sufficiently powered
to evaluate these subgroup effects. Last, a single
measure of social support only does not address
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the potential impact of change in social support or
adherence over time.
Given the importance of the early treatment
phase, great care should be taken to identify
patients at risk for non-adherence in order to
establish these patients in treatment. Our results
of lower antidepressant adherence rates in African-
American women with low social support suggest
the need for culturally sensitive, gender-specific,
depression care interventions that are sensitive to
race and gender differences. Targeted interventions
for those individuals with low levels of support
could include social skills training, assessment
of quality and quantity of relationships, and
encouragement of participation in community and
patient advocacy groups may help to improve
adherence. Utilization of tailored interventions,
such as the Treatment Initiation and Participation
Program (TIP) focused in primary care patients,
may help address these barriers to adherence (Sirey
et al., 2010). Future research on the specific
variables and factors within social support that
most influence treatment adherence could be
helpful in better targeting these interventions.
Conclusions
The present study demonstrates a significant
relationship between race, gender, perceived social
support, and antidepressant medication adherence
among older adults. African-American women with
low social support had the lowest rates medication
adherence and may represent a particularly
vulnerable population in regards to depression
treatment adherence. Targeted interventions for
individuals with low social support should be
sensitive to racial and gender differences.
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